Senate must question Heidi Overton on abortion drug rules

The Washington Examiner reports that the Senate should scrutinize Heidi Overton’s nomination to lead the FDA regarding the agency's policy on mifepristone. Critics argue that eliminating in-person dispensing requirements for abortion pills has facilitated abuse and coercion, citing specific cases of harm. The article urges senators to demand answers on whether the federal government should continue defending these policies before confirming Overton to the top health position.